Intellia Therapeutics NTLA Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Intellia Therapeutics (NTLA) reported accretion (amortization) of discounts and premiums, investments of $535K in Q1 2026.
- How has Intellia Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Intellia Therapeutics's accretion (amortization) of discounts and premiums, investments decreased by 76.5% year-over-year, from $2.28M to $535K.
- What is the long-term trend for Intellia Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Intellia Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a -8.3% compound annual growth rate (CAGR), from -$7.6M to $5.86M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to the carrying value of investment securities to reflect the amortization of premiums or accretion of discounts over the life of the instrument. It reconciles the difference between the purchase price and the face value of debt securities held as investments. This adjustment is essential for accurately reflecting interest income earned on the investment portfolio in the operating cash flow.